INKT (MiNK Therapeutics) Other Current Liabilities: $2.57 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INKT MiNK Therapeutics Inc INKT
31 GF Score
Price $10.69
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics Other Current Liabilities?

MiNK Therapeutics INKT -1.39% 31 Other Current Liabilities is $2.57 Mil as of Mar. 2026. GuruFocus rates INKT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

MiNK Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $2.57 Mil.

MiNK Therapeutics's quarterly other current liabilities increased from Sep. 2025 ($2.76 Mil) to Dec. 2025 ($2.85 Mil) but then declined from Dec. 2025 ($2.85 Mil) to Mar. 2026 ($2.57 Mil).

MiNK Therapeutics's annual other current liabilities declined from Dec. 2023 ($2.45 Mil) to Dec. 2024 ($2.36 Mil) but then increased from Dec. 2024 ($2.36 Mil) to Dec. 2025 ($2.85 Mil).

MiNK Therapeutics Other Current Liabilities Related Terms

MiNK Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics Other Current Liabilities Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 5.76 2.62 2.45 2.36 2.85

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.37 2.48 2.76 2.85 2.57
INKT
31GF Score
MiNK Therapeutics Inc INKT
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $2.57 Mil mean?
MiNK Therapeutics (INKT) has a Other Current Liabilities of $2.57 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MiNK Therapeutics.
Is MiNK Therapeutics' Other Current Liabilities too high?
MiNK Therapeutics' current Other Current Liabilities is $2.57 Mil. Overall, MiNK Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' Other Current Liabilities compare to BOLD and FLNA?
MiNK Therapeutics' Other Current Liabilities of $2.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MiNK Therapeutics. MiNK Therapeutics's current Other Current Liabilities is $2.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current Other Current Liabilities of $2.57 Mil. The current Other Current Liabilities is $2.57 Mil. MiNK Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current Other Current Liabilities is $2.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges 6Q40:Germany
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
31GF Score

Get the complete analysis for INKT

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.69
Price